Recent advances in tuberculosis treatment: Towards shorter, safer, and more effective therapies

Tuberculosis (TB), caused by Mycobacterium tuberculosis, is the leading infectious cause of death globally. Although effective treatments are available, treatment length, drug toxicity, and the emergence of drug-resistant strains have challenged TB control efforts. Current clinical trials are focused on developing shorter, safer, and more effective regimens that incorporate both new and repurposed agents for the treatment of TB. This narrative review provides an overview of current and emerging treatment options for drug-susceptible, drug-resistant, and latent TB based on recent clinical trials and WHO guidelines.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Published
2026-01-14
DOI
https://doi.org/10.1016/j.jctube.2026.100582
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Recent advances in tuberculosis treatment: Towards shorter, safer, and more effective therapies

Greta L. Becker, JBrooks Jackson, Katherine Timboe
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Tuberculosis Research and Epidemiology
article

Recent advances in tuberculosis treatment: Towards shorter, safer, and more effective therapies

Greta L. Becker, JBrooks Jackson, Katherine Timboe
article en

Abstract

Tuberculosis (TB), caused by Mycobacterium tuberculosis, is the leading infectious cause of death globally. Although effective treatments are available, treatment length, drug toxicity, and the emergence of drug-resistant strains have challenged TB control efforts. Current clinical trials are focused on developing shorter, safer, and more effective regimens that incorporate both new and repurposed agents for the treatment of TB. This narrative review provides an overview of current and emerging treatment options for drug-susceptible, drug-resistant, and latent TB based on recent clinical trials and WHO guidelines.

Journal of Clinical Tuberculosis and Other Mycobacterial DiseasesVol. 42
University of Iowa (US)
Good health and well-being
Openalex Percentile: Top 85%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.